196 related articles for article (PubMed ID: 16736024)
1. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.
Zelek L; Yovine A; Brain E; Turpin F; Taamma A; Riofrio M; Spielmann M; Jimeno J; Misset JL
Br J Cancer; 2006 Jun; 94(11):1610-4. PubMed ID: 16736024
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Twelves C; Hoekman K; Bowman A; Vermorken JB; Anthoney A; Smyth J; van Kesteren C; Beijnen JH; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
Eur J Cancer; 2003 Sep; 39(13):1842-51. PubMed ID: 12932661
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Sessa C; De Braud F; Perotti A; Bauer J; Curigliano G; Noberasco C; Zanaboni F; Gianni L; Marsoni S; Jimeno J; D'Incalci M; Dall'ó E; Colombo N
J Clin Oncol; 2005 Mar; 23(9):1867-74. PubMed ID: 15774779
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of ET-743: the French experience.
Brain EG
Anticancer Drugs; 2002 May; 13 Suppl 1():S11-4. PubMed ID: 12173489
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
Taamma A; Misset JL; Riofrio M; Guzman C; Brain E; Lopez Lazaro L; Rosing H; Jimeno JM; Cvitkovic E
J Clin Oncol; 2001 Mar; 19(5):1256-65. PubMed ID: 11230466
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.
Awada A; Cortés J; Martín M; Aftimos P; Oliveira M; López-Tarruella S; Espie M; Lardelli P; Extremera S; Fernández-García EM; Delaloge S
Clin Breast Cancer; 2016 Oct; 16(5):364-371. PubMed ID: 27266804
[TBL] [Abstract][Full Text] [Related]
9. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.
Ryan DP; Puchalski T; Supko JG; Harmon D; Maki R; Garcia-Carbonero R; Kuhlman C; Winkelman J; Merriam P; Quigley T; Jimeno J; Manola J; Demetri GD
Oncologist; 2002; 7(6):531-8. PubMed ID: 12490740
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
van Kesteren C; Twelves C; Bowman A; Hoekman K; López-Lázaro L; Jimeno J; Guzman C; Mathôt RA; Simpson A; Vermorken JB; Smyth J; Schellens JH; Hillebrand MJ; Rosing H; Beijnen JH
Anticancer Drugs; 2002 Apr; 13(4):381-93. PubMed ID: 11984084
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK
Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
14. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
16. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.
Delaloge S; Wolp-Diniz R; Byrski T; Blum JL; Gonçalves A; Campone M; Lardelli P; Kahatt C; Nieto A; Cullell-Young M; Lubinski J
Ann Oncol; 2014 Jun; 25(6):1152-8. PubMed ID: 24692579
[TBL] [Abstract][Full Text] [Related]
17. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Garcia-Carbonero R; Supko JG; Manola J; Seiden MV; Harmon D; Ryan DP; Quigley MT; Merriam P; Canniff J; Goss G; Matulonis U; Maki RG; Lopez T; Puchalski TA; Sancho MA; Gomez J; Guzman C; Jimeno J; Demetri GD
J Clin Oncol; 2004 Apr; 22(8):1480-90. PubMed ID: 15084621
[TBL] [Abstract][Full Text] [Related]
18. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
Krasner CN; McMeekin DS; Chan S; Braly PS; Renshaw FG; Kaye S; Provencher DM; Campos S; Gore ME
Br J Cancer; 2007 Dec; 97(12):1618-24. PubMed ID: 18000504
[TBL] [Abstract][Full Text] [Related]
19. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
Le Cesne A; Blay JY; Judson I; Van Oosterom A; Verweij J; Radford J; Lorigan P; Rodenhuis S; Ray-Coquard I; Bonvalot S; Collin F; Jimeno J; Di Paola E; Van Glabbeke M; Nielsen OS
J Clin Oncol; 2005 Jan; 23(3):576-84. PubMed ID: 15659504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
